These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31801071)

  • 1. The Immunological Organ Environment Dictates the Molecular and Cellular Pathways of Cytotoxic Antibody Activity.
    Gordan S; Albert H; Danzer H; Lux A; Biburger M; Nimmerjahn F
    Cell Rep; 2019 Dec; 29(10):3033-3046.e4. PubMed ID: 31801071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate receptor-mediated cellular cytotoxicity against malignant human glioma cells.
    Nitta T; Yagita H; Sato K; Okumura K
    Neurosurgery; 1991 Mar; 28(3):394-9. PubMed ID: 2011221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities.
    Nimmerjahn F; Gordan S; Lux A
    Trends Immunol; 2015 Jun; 36(6):325-36. PubMed ID: 25981969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
    Li G; Zhang L; Chen E; Wang J; Jiang X; Chen JH; Wickman G; Amundson K; Bergqvist S; Zobel J; Buckman D; Baxi SM; Bender SL; Casperson GF; Hu-Lowe DD
    Cancer Res; 2010 Dec; 70(24):10243-54. PubMed ID: 21159645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
    Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
    Front Immunol; 2019; 10():562. PubMed ID: 30984171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
    Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
    Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
    Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fcγ Receptor- and Complement Receptor 3-Dependent Mechanisms.
    Amash A; Wang L; Wang Y; Bhakta V; Fairn GD; Hou M; Peng J; Sheffield WP; Lazarus AH
    J Immunol; 2016 Apr; 196(8):3331-40. PubMed ID: 26944929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
    Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
    Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
    J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophages are the dominant effector cells responsible for IgG-mediated passive systemic anaphylaxis challenged by natural protein antigen in BALB/c and C57BL/6 mice.
    Jiao D; Liu Y; Lu X; Liu B; Pan Q; Liu Y; Liu Y; Zhu P; Fu N
    Cell Immunol; 2014; 289(1-2):97-105. PubMed ID: 24751884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A monoclonal antibody (RH1-38) which inhibits multiple systems of cell-mediated cytotoxicity--I. Identification of a novel epitope on a killer cell surface bimolecular complex important in the cytotoxic response.
    Hall RE
    Mol Immunol; 1985 Jul; 22(7):757-64. PubMed ID: 2412110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of effector cells mediating IgG and IgM antibody-dependent cellular cytotoxicity.
    Zöller M; Andrighetto GC; Heyman B; Lamon EW; Wigzell H
    Scand J Immunol; 1983 Jan; 17(1):19-27. PubMed ID: 6601820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How immunoglobulin G antibodies kill target cells: revisiting an old paradigm.
    Biburger M; Lux A; Nimmerjahn F
    Adv Immunol; 2014; 124():67-94. PubMed ID: 25175773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.